A physiological toxicokinetic model for inhaled propylene oxide in rat and human with special emphasis on the nose.
Chronic exposure to high concentrations of PO induced inflammation in the respiratory nasal mucosa (RNM) of rodents and, for concentrations >or= 300 ppm, caused nasal tumors. Considering the nose to be the most relevant target organ for PO-induced tumorigenicity, we developed a physiological toxicokinetic model for PO in rats and humans. It includes compartments for arterial, venous, and pulmonary blood, liver, muscle, fat, richly perfused tissues, lung, and nose. It simulates inhalation of PO, its distribution into tissues by blood flow, and its elimination by exhalation and metabolism. In nose, lung, and liver of rats, PO conjugation with glutathione (GSH), PO-induced GSH depletion, and formation of PO adducts to DNA are described. Also modeled are PO adducts to hemoglobin of rats and humans. Required partition coefficients and metabolic parameters were derived experimentally or from publications. In rats, simulated PO concentrations in blood and GSH levels in tissues agreed with measured data. If compared with reported values, levels of adducts with hemoglobin were underpredicted up to a factor of about 2. Adducts with DNA differed up to a factor of 3. Hemoglobin adducts predicted for PO-exposed workers were 1.5-1.9 times higher than the reported ones. Considering identical conditions of PO exposure, similar PO concentrations in RNM were modeled for rats and humans. Also, PO concentrations in blood, about 1/30th of those in RNM, were similar in both species. Since the model was evaluated on all available data in rats and humans, we consider it to be useful for estimating the risk from inhalation exposure to PO.
Csanády
György A
GA
Institute of Toxicology, GSF National Research Center for Environment and Health, D-85764 Neuherberg, Germany.
Filser
Johannes G
JG
D000393:Air Pollutants / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002138:Calibration; D003198:Computer Simulation; D018736:DNA Adducts / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004852:Epoxy Compounds / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D005069:Evaluation Studies as Topic; D005978:Glutathione / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D019570:Inhalation Exposure; D008297:Male; D008954:Models, Biological; D009297:Nasal Mucosa / Q000378:metabolism*; D009666:Nose / Q000187:drug effects; D009669:Nose Neoplasms / Q000139:chemically induced*; D051381:Rats; D011916:Rats, Inbred F344; D015203:Reproducibility of Results; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D013997:Time Factors; D014018:Tissue Distribution
D000393:Air Pollutants; D015415:Biomarkers; D018736:DNA Adducts; D004852:Epoxy Compounds; D006454:Hemoglobins; D005978:Glutathione; C009068:propylene oxide